Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TET1-DBD
- Development stage
- Preclinical
- Lead developer
- Indiana University
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Gene Therapies
- Administration
- Intravenous, Oral, Topical, Intraperitoneal, Intravesical, Intrathecal, Intramuscular, Subcutaneous, Intradermal, Parenteral
01
Overview
TET1-DBD is an engineered fusion construct consisting of the catalytic domain of the ten-eleven translocation 1 (TET1) methylcytosine dioxygenase and the DNA-binding domain (DBD) of the transcription factor Snail [1396]. Developed by researchers at Northwestern University and Indiana University, this epigenetic editing tool is designed to selectively induce DNA demethylation at promoters targeted by Snail [1396]. By targeting Snail-binding sites, TET1-DBD promotes localized hypomethylation, reactivating epithelial genes such as E-cadherin and suppressing mesenchymal markers like fibronectin and vimentin, thereby blocking the epithelial-to-mesenchymal transition (EMT) program in ovarian and breast cancer models [1396].
- Other names
- TET1-DBDTET-1-DBDTET 1-DBDTET1-Snail-DBDTET-1-Snail-DBDTET 1-Snail-DBD
02
Targets
TET1 (Methylcytosine dioxygenase TET1)DNA at the programmed genomic locus5mC (5-methylcytosine in DNA)
Beyond the preview
Go deeper on TET1-DBD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TET1-DBD.